Overview

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

Status:
RECRUITING

Trial end date:
2029-06-01

Target enrollment:

Participant gender:

Summary

An open-label, Phase Ib dose escalation and dose expansion clinical trial evaluating the safety and efficacy of CBP-1019 combinations in patients with solid tumors of epithelial origin.

Phase:

PHASE1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Bevacizumab
enzalutamide
Fluorouracil
Leucovorin
Oxaliplatin
pembrolizumab